Another Update at the end of January for cervical cancer, then I believe an update on the CIN trial in February. Just like Incyte is getting approved for Mylofibrosis, a small indication, then they are trying to get approved for PV which is a precursor to Mylofibrosis and a much larger indication. ADXS is trying for cervical cancer, then a precursor which is much larger, CIN. Still a lot of work to be done, but I would be very suprised if later results of the Phase 2 are not outstanding. I would also be very surprised if they do not have a major licensing deal in the next 6 months. After all, they are in the Top 10 licensable platforms.